Previous close | 0.400 |
Open | 0.370 |
Bid | 0.355 x N/A |
Ask | 0.390 x N/A |
Day's range | 0.350 - 0.400 |
52-week range | 0.250 - 2.030 |
Volume | |
Avg. volume | 47,327 |
Market cap | 150.72M |
Beta (5Y monthly) | -0.72 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CANbridge Pharmaceuticals Inc. (HKEX:1228), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced today that the National Medical Products Administration of China (NMPA) has accepted the New Drug Application (NDA) for CAN108 (Maralixibat Chloride Oral Solution /迈芮倍®/LIVMARLI®) for the treatment of cholestatic pruritus in patients two months of age and older
BEIJING & BURLINGTON, Mass., July 03, 2023--CANbridge Pharma to continue CAN008 Ph 2 trial in glioblastoma multiforme in China, based on independent data monitoring committee interim analysis.
BEIJING & BURLINGTON, Mass., June 26, 2023--CANbridge reports positive preliminary data on Phase 1b CAN106 (omoprubart) trial in PNH in China.